rotecting Perforomist Inhalation Solution. In addition to EpiPen Auto-Injector and Perforomist Inhalation Solution, Mylan Specialty also markets ULTIVA, which is an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures and is generally administered by an infusion device. Customers and Marketing Generics Segment In North America, the company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. The company also markets its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. These customers, called indirect customers, purchase its products primarily through its wholesale customers. In Europe and Rest of World, generic pharmaceuticals are sold to wholesalers, independent pharmacies and, in certain countries, directly to hospitals. The company’s API are sold primarily to generic FDF manufacturers throughout the world, as well as to other subsidiaries. Specialty Segment Mylan Specialty markets its products to various different customer audiences in the U.S., including health care practitioners, wholesalers, pharmacists and pharmacy chains, hospitals, payers, pharmacy benefit manager, health maintenance organizations, home health care, long-term care, and patients. Major Customers During 2014, the company’s customers included McKesson Corporation; AmeriSourceBergen Corporation; and Cardinal Health, Inc. Seasonality Certain parts of the company’s business are affected by seasonality, primarily the Specialty segment and Rest of World within its Generics segment. Research and Development For the year ended December 31, 2014, the company’s research and development spending was $582 million. Government Regulations In Japan, the company is governed by various laws and regulations, including the Pharmaceutical Affairs Law (Law No. 145, 1960), as amended by the Pharmaceuticals and Medical Devices Law (PMDL), and the Products Liability Law (Law No. 85, 1994). Under the amended PMDL, the retailing or supply of a pharmaceutical that a person has manufactured (including manufacturing under license) or imported is defined as marketing, and in order to market pharmaceuticals, one has to obtain a license, which the company refers to herein as a Marketing License, from the Minister of the Ministry of Health, Labor and Welfare. History Mylan N.V. was founded in 1961.
mylan nv (MYL:NASDAQ GS)
Potters Bar, EN6 1AG
Phone: 44 1707 853000
Fax: 44 1707 643148www.mylan.com
|Astellas Pharma Inc||¥1,750 JPY||+16.00|
|Becton Dickinson and Co||$150.25 USD||-1.04|
|Perrigo Co PLC||$149.39 USD||-1.10|
|Valeant Pharmaceuticals International Inc||C$121.18 CAD||+0.83|
|WW Grainger Inc||$200.54 USD||+0.89|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MYLAN NV, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.